2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin's and Non-Hodgkin Lymphomas.
PET Clin
; 19(4): 447-462, 2024 Oct.
Article
em En
| MEDLINE
| ID: mdl-38945737
ABSTRACT
The 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography combined with computed tomography (PET/CT) has contributed to outcome improvement of patients with lymphoma. The use of [18F]FDG PET/CT for staging and response assessment is successfully applied both in routine clinical practice and in clinical trials. The challenges lie in enhancing the outcomes of lymphoma patients, particularly those with advanced or refractory/relapsed disease, and to minimize the long-term toxicity associated with treatments, including radiation therapy. The objective of this review article is to present contemporary data on the use of [18F]FDG PET/CT for treatment assessment of aggressive lymphomas.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Linfoma não Hodgkin
/
Doença de Hodgkin
/
Compostos Radiofarmacêuticos
/
Fluordesoxiglucose F18
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article